Stay updated on MG1-MAGEA3 Combo with Pembrolizumab for NSCLC Clinical Trial
Sign up to get notified when there's something new on the MG1-MAGEA3 Combo with Pembrolizumab for NSCLC Clinical Trial page.

Latest updates to the MG1-MAGEA3 Combo with Pembrolizumab for NSCLC Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedThe page now shows Revision: v3.4.2, replacing v3.4.1, indicating a platform update with no substantive changes to study information. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check20 days agoChange DetectedRevision updated from v3.4.0 to v3.4.1.SummaryDifference0.1%

- Check27 days agoChange DetectedShow glossary was added and labels were updated to 'Last Update Submitted that Met QC Criteria' and 'No FEAR Act Data' with standardized capitalization. 'Revision: v3.4.0' was added and 'Revision: v3.3.4' was removed.SummaryDifference0.2%

- Check42 days agoChange DetectedRevision: v3.3.4 added, replacing the previous v3.3.3. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check63 days agoChange DetectedLocations sections for Alberta, New Brunswick, and Ontario have been added under the Study Locations, and the prior provincial location subsections have been removed. The page revision tag has been updated to v3.3.3.SummaryDifference0.4%

- Check91 days agoChange DetectedThe Publications section now includes a note that items are automatically filled from PubMed. The revision tag updates from v3.2.0 to v3.3.2.SummaryDifference0.1%

Stay in the know with updates to MG1-MAGEA3 Combo with Pembrolizumab for NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the MG1-MAGEA3 Combo with Pembrolizumab for NSCLC Clinical Trial page.